Glioblastoma stem-like cells (GSCs) are critical for the aggressiveness and progression of glioblastoma (GBM) and contribute to its resistance to adjuvant treatment. MicroRNAs (miRNAs) are small, non-coding RNAs controlling gene expression at the post-transcriptional level, which are known to be important regulators of the stem-like features. Moreover, miRNAs have been previously proved to be promising diagnostic biomarkers in several cancers including GBM. Using global expression analysis of miRNAs in 10 paired in-vitro as well as in-vivo characterized primary GSC and non-stem glioblastoma cultures, we identified a miRNA signature associated with the stem-like phenotype in GBM. 51 most deregulated miRNAs classified the cell cultures into GSC and non-stem cell clusters and identified a subgroup of GSC cultures with more pronounced stem-cell characteristics. The importance of the identified miRNA signature was further supported by demonstrating that a Risk Score based on the expression of seven miRNAs overexpressed in GSC predicted overall survival in GBM patients in the TCGA dataset independently of the IDH1 status. In summary, we identified miRNAs differentially expressed in GSCs and described their association with GBM patient survival. We propose that these miRNAs participate on GSC features and could represent helpful prognostic markers and potential therapeutic targets in GBM.

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Faculty of Medicine Masaryk University Brno Czech Republic

Department of Neurosurgery University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

Department of Neurosurgery University Hospital Ostrava Ostrava Czech Republic

Department of Pathology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

Institute of Biochemistry and Experimental Oncology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. PubMed DOI

Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CLL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015;29:1203–1217. doi: 10.1101/gad.261982.115. PubMed DOI PMC

Jackson M, Hassiotou F, Nowak A. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis. 2015;36:177–185. doi: 10.1093/carcin/bgu243. PubMed DOI

Rahman M, et al. Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines. Anat. Cell Biol. 2015;48:25–35. doi: 10.5115/acb.2015.48.1.25. PubMed DOI PMC

Pavon, L. F. et al. In vitro Analysis of Neurospheres Derived from Glioblastoma Primary Culture: A Novel Methodology Paradigm. Front. Neurol. 4 (2014). PubMed PMC

Wakimoto H, et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro-Oncol. 2012;14:132–144. doi: 10.1093/neuonc/nor195. PubMed DOI PMC

Iacopino F, et al. Isolation of Cancer Stem Cells from Three Human Glioblastoma Cell Lines: Characterization of Two Selected Clones. PLoS ONE. 2014;9:e105166. doi: 10.1371/journal.pone.0105166. PubMed DOI PMC

Brescia P, et al. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells Dayt. Ohio. 2013;31:857–869. doi: 10.1002/stem.1317. PubMed DOI

Zhang, W., Chen, H., Lv, S. & Yang, H. High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma. Mol. Neurobiol, 10.1007/s12035-015-9187-1 (2015). PubMed

Dahlrot RH, et al. Clinical value of CD133 and nestin in patients with glioma: a population-based study. Int. J. Clin. Exp. Pathol. 2014;7:3739–3751. PubMed PMC

Miconi G, et al. Immunophenotypic characterization of human glioblastoma stem cells: correlation with clinical outcome. J. Cell. Biochem. 2015;116:864–876. doi: 10.1002/jcb.25043. PubMed DOI

Kong BH, et al. Prognostic value of glioma cancer stem cell isolation in survival of primary glioblastoma patients. Stem Cells Int. 2014;2014:838950. doi: 10.1155/2014/838950. PubMed DOI PMC

Virant-Klun I, Ståhlberg A, Kubista M, Skutella T. MicroRNAs: From Female Fertility, Germ Cells, and Stem Cells to Cancer in Humans. Stem Cells Int. 2016;2016:3984937. PubMed PMC

Besse A, Sana J, Fadrus P, Slaby O. MicroRNAs involved in chemo- and radioresistance of high-grade gliomas. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 2013;34:1969–1978. doi: 10.1007/s13277-013-0772-5. PubMed DOI

Yang HW, Xing H, Johnson MD. A major role for microRNAs in glioblastoma cancer stem-like cells. Arch. Pharm. Res. 2015;38:423–434. doi: 10.1007/s12272-015-0574-y. PubMed DOI

Kleinová R, Slabý O, Šána J. [The Relevance of MicroRNAs in GlioblastomaStem Cells] Klin. Onkol. Cas. Ceské Slov. Onkol. Spolecnosti. 2015;28:338–344. PubMed

Brower JV, Clark PA, Lyon W, Kuo JS. MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells. Neurochem. Int. 2014;77:68–77. doi: 10.1016/j.neuint.2014.06.002. PubMed DOI PMC

Aldaz B, et al. Involvement of miRNAs in the differentiation of human glioblastoma multiforme stem-like cells. PloS One. 2013;8:e77098. doi: 10.1371/journal.pone.0077098. PubMed DOI PMC

Fareh M, et al. The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ. 2012;19:232–244. doi: 10.1038/cdd.2011.89. PubMed DOI PMC

Sana J, et al. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients. Carcinogenesis. 2014;35:2756–2762. doi: 10.1093/carcin/bgu212. PubMed DOI

Lakomy R, et al. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci. 2011;102:2186–2190. doi: 10.1111/j.1349-7006.2011.02092.x. PubMed DOI PMC

Therneau T. Modeling Survival Data: Extending the Cox Model. Springer, New York 2000.

Therneau T. A Package for Survival Analysis in S. R Package Version 2.37-6, http://CRAN.R-project.org/package=survival (30 October 2014, date last accessed) 2014.

Aum DJ, et al. Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurg. Focus. 2014;37:E11. doi: 10.3171/2014.9.FOCUS14521. PubMed DOI

Eder K, Kalman B. Molecular heterogeneity of glioblastoma and its clinical relevance. Pathol. Oncol. Res. POR. 2014;20:777–787. doi: 10.1007/s12253-014-9833-3. PubMed DOI

Bayin NS, Modrek AS, Placantonakis DG. Glioblastoma stem cells: Molecular characteristics and therapeutic implications. World J. Stem Cells. 2014;6:230–238. doi: 10.4252/wjsc.v6.i2.230. PubMed DOI PMC

Yin C, Lv S, Chen X, Guo H. The role of glioma stem cells in glioma tumorigenesis. Front. Biosci. Landmark Ed. 2014;19:818–824. doi: 10.2741/4249. PubMed DOI

Bao S, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760. doi: 10.1038/nature05236. PubMed DOI

Cheng L, et al. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J. 2011;30:800–813. doi: 10.1038/emboj.2011.10. PubMed DOI PMC

Floyd D, Purow B. Micro-masters of glioblastoma biology and therapy: increasingly recognized roles for microRNAs. Neuro-Oncol. 2014;16:622–627. doi: 10.1093/neuonc/nou049. PubMed DOI PMC

Lee J, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9:391–403. doi: 10.1016/j.ccr.2006.03.030. PubMed DOI

Gangemi RMR, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells Dayt. Ohio. 2009;27:40–48. doi: 10.1634/stemcells.2008-0493. PubMed DOI

Yuva-Aydemir Y, Simkin A, Gascon E, Gao F-B. MicroRNA-9: functional evolution of a conserved small regulatory RNA. RNA Biol. 2011;8:557–564. doi: 10.4161/rna.8.4.16019. PubMed DOI PMC

Lagos-Quintana M, et al. Identification of tissue-specific microRNAs from mouse. Curr. Biol. CB. 2002;12:735–739. doi: 10.1016/S0960-9822(02)00809-6. PubMed DOI

Bonev B, Pisco A, Papalopulu N. MicroRNA-9 reveals regional diversity of neural progenitors along the anterior-posterior axis. Dev. Cell. 2011;20:19–32. doi: 10.1016/j.devcel.2010.11.018. PubMed DOI PMC

Bonev B, Stanley P, Papalopulu N. MicroRNA-9 Modulates Hes1 ultradian oscillations by forming a double-negative feedback loop. Cell Rep. 2012;2:10–18. doi: 10.1016/j.celrep.2012.05.017. PubMed DOI PMC

Coolen M, Thieffry D, Drivenes Ø, Becker TS, Bally-Cuif L. miR-9 controls the timing of neurogenesis through the direct inhibition of antagonistic factors. Dev. Cell. 2012;22:1052–1064. doi: 10.1016/j.devcel.2012.03.003. PubMed DOI

Roese-Koerner B, et al. Reciprocal Regulation between Bifunctional miR-9/9(*) and its Transcriptional Modulator Notch in Human Neural Stem Cell Self-Renewal and Differentiation. Stem Cell Rep. 2016;7:207–219. doi: 10.1016/j.stemcr.2016.06.008. PubMed DOI PMC

Tan S-L, Ohtsuka T, González A, Kageyama R. MicroRNA9 regulates neural stem cell differentiation by controlling Hes1 expression dynamics in the developing brain. Genes Cells Devoted Mol. Cell. Mech. 2012;17:952–961. doi: 10.1111/gtc.12009. PubMed DOI

Roese-Koerner B, Stappert L, Koch P, Brüstle O, Borghese L. Pluripotent stem cell-derived somatic stem cells as tool to study the role of microRNAs in early human neural development. Curr. Mol. Med. 2013;13:707–722. doi: 10.2174/1566524011313050003. PubMed DOI

Schraivogel D, et al. CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J. 2011;30:4309–4322. doi: 10.1038/emboj.2011.301. PubMed DOI PMC

Munoz, J. L., Rodriguez-Cruz, V. & Rameshwar, P. High expression of miR-9 in CD133(+) glioblastoma cells in chemoresistance to temozolomide. J. Cancer Stem Cell Res. 3 (2015). PubMed PMC

Staahl BT, et al. Kinetic analysis of npBAF to nBAF switching reveals exchange of SS18 with CREST and integration with neural developmental pathways. J. Neurosci. Off. J. Soc. Neurosci. 2013;33:10348–10361. doi: 10.1523/JNEUROSCI.1258-13.2013. PubMed DOI PMC

Xue Q, et al. miR-9 and miR-124 synergistically affect regulation of dendritic branching via the AKT/GSK3β pathway by targeting Rap2a. Sci. Rep. 2016;6:26781. doi: 10.1038/srep26781. PubMed DOI PMC

Brett JO, Renault VM, Rafalski VA, Webb AE, Brunet A. The microRNA cluster miR-106b~25 regulates adult neural stem/progenitor cell proliferation and neuronal differentiation. Aging. 2011;3:108–124. doi: 10.18632/aging.100285. PubMed DOI PMC

Yu D, Shin H-S, Lee YS, Lee YC. miR-106b modulates cancer stem cell characteristics through TGF-β/Smad signaling in CD44-positive gastric cancer cells. Lab. Investig. J. Tech. Methods Pathol. 2014;94:1370–1381. doi: 10.1038/labinvest.2014.125. PubMed DOI

Chang S-J, et al. MicroRNA-34a modulates genes involved in cellular motility and oxidative phosphorylation in neural precursors derived from human umbilical cord mesenchymal stem cells. BMC Med. Genomics. 2011;4:65. doi: 10.1186/1755-8794-4-65. PubMed DOI PMC

Lu Y, et al. Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells. Cell Stem Cell. 2014;15:92–101. doi: 10.1016/j.stem.2014.04.002. PubMed DOI PMC

Stappert L, et al. MicroRNA-based promotion of human neuronal differentiation and subtype specification. PloS One. 2013;8:e59011. doi: 10.1371/journal.pone.0059011. PubMed DOI PMC

Tezcan G, et al. microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. Cell. Mol. Neurobiol. 2014;34:679–692. doi: 10.1007/s10571-014-0050-0. PubMed DOI PMC

Melguizo C, et al. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J. Transl. Med. 2012;10:250. doi: 10.1186/1479-5876-10-250. PubMed DOI PMC

Kim K-J, et al. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathol. Off. J. Jpn. Soc. Neuropathol. 2011;31:494–502. doi: 10.1111/j.1440-1789.2010.01194.x. PubMed DOI

Pallini R, et al. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer. 2011;117:162–174. doi: 10.1002/cncr.25581. PubMed DOI

Joo KM, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab. Investig. J. Tech. Methods Pathol. 2008;88:808–815. doi: 10.1038/labinvest.2008.57. PubMed DOI

Li L, Bhatia R. Stem cell quiescence. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2011;17:4936–4941. doi: 10.1158/1078-0432.CCR-10-1499. PubMed DOI PMC

Fael Al-Mayhani TM, et al. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J. Neurosci. Methods. 2009;176:192–199. doi: 10.1016/j.jneumeth.2008.07.022. PubMed DOI

Pollard SM, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009;4:568–580. doi: 10.1016/j.stem.2009.03.014. PubMed DOI

Busek P, et al. Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity. Int. J. Biochem. Cell Biol. 2012;44:738–747. doi: 10.1016/j.biocel.2012.01.011. PubMed DOI

Trylcova J, et al. Effect of cancer-associated fibroblasts on the migration of glioma cells in vitro. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 2015;36:5873–5879. doi: 10.1007/s13277-015-3259-8. PubMed DOI

Team,RC. R: A Language and Environment for Statistical Computing. http://www.R-project.org/ (Foundation for Statistical Computing, 2013).

Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinforma. Oxf. Engl. 2010;26:2363–2367. doi: 10.1093/bioinformatics/btq431. PubMed DOI PMC

Smyth G. Limma: linear models for microarray data In Gentleman R, Carey V, Dudoit S, et al. Bioinformatics and Computational Biology Solutions Using R and Bioconductor (Gentleman, R. et al.) 397–420 (Springer, 2005).

Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–1068. doi: 10.1038/nature07385. PubMed DOI PMC

Lauss M. rocc: ROC Based Classification. R Package Version 1.2. http://CRAN.R-project.org/package=rocc (30 October 2014, date last accessed) (2010).

Microtubule-associated NAV3 regulates invasive phenotypes in glioblastoma cells

Fibrillar extracellular matrix produced by pericyte-like cells facilitates glioma cell dissemination

Molecularly targeted protease-activated probes for visualization of glioblastoma: a comparison with 5-ALA

Small RNA Sequencing Identifies PIWI-Interacting RNAs Deregulated in Glioblastoma-piR-9491 and piR-12488 Reduce Tumor Cell Colonies In Vitro

Regulation of Fibroblast Activation Protein by Transforming Growth Factor Beta-1 in Glioblastoma Microenvironment